Идёт набор NCT07308639

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

— Наблюдательное Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: anti-VEGF medication.
Кому может быть актуально: Состояния в реестре: Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO). Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Германия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

DATA-INSIGHT: Data Analysis for Treatment Assessment and Evaluation of New Sources for Evidence Generation in German Healthcare System

Обзор

The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that affects the central part of the retina and can cause vision loss in older adults. DME (diabetic macular edema): a swelling in the central part of the retina caused by diabetes, which can also lead to vision problems. RVO (retinal vein occlusion): a blockage of the veins in the retina, which can cause sudden vision loss. Researchers will look at data collected from 2009 to 2024 to see how often these diseases occur (incidence) and how many people have them at a given time (prevalence). They will use two large sets of health data from Germany, called FDZ and FDGP. The main question is: How do the numbers of new and existing cases of nAMD, DME, and RVO compare between the two data sources (FDZ and FDGP) in Germany from 2009 to 2024? The study also wants to find out if factors like age, other health problems, and medications affect how common these eye diseases are. Another goal is to see how many people with these eye diseases are treated with a type of medicine called anti-VEGF, which is used to slow down or stop vision loss. In summary, this study will help us understand how these eye diseases affect people in Germany, how they are treated, and whether different groups of people are more likely to get them.

Вмешательства

Препарат anti-VEGF medication
according to local label and treating physician

Первичные конечные точки

incidence of nAMD, DME and RVO of FDZ and FDPG in Germany [Срок оценки: 1 Jan 2009 - 31 Dec 2024]
prevalence of nAMD, DME and RVO in Germany [Срок оценки: 1 Jan 2009 - 31 Dec 2024]

Вторичные конечные точки (4)

incidence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and data sources [Срок оценки: 1 Jan 2009 - 31 Dec 2024]
prevalence of nAMD, DME and RVO of FDZ and FDPG in Germany influenced by demographics, comorbidities, medications and data sources [Срок оценки: 1 Jan 2009 - 31 Dec 2024]
Number of patients with nAMD, DME, and RVO treated with anti-VEGF medications [Срок оценки: 1 Jan 2009 - 31 Dec 2024]
Proportion of patients with nAMD, DME, and RVO treated with anti-VEGF medications [Срок оценки: 1 Jan 2009 - 31 Dec 2024]

Критерии участия

Критерии включения

At least one diagnosis of nAMD, DME and RVO in the timeframe 01 JAN 2009 until 31 DEC 2024
nAMD patients aged ≥ 50 years
DME patients aged ≥18 years
RVO patients aged ≥18 years
Participants living in Germany covered by statutory health insurance or private health insurance